Effect of Paricalcitol (cas 131918-61-1) on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism
-
Add time:08/02/2019 Source:sciencedirect.com
IntroductionSecondary hyperparathyroidism is highly prevalent in kidney transplant recipients, and commonly results in hypercalcaemia; an association to osteopenia and bone fractures has also been observed. Paricalcitol (cas 131918-61-1) has proved effective to control secondary hyperparathyroidism in chronic kidney disease in both dialysed and non-dialysed patients, with a low hypercalcaemia incidence. Currently available experience on paricalcitol use in kidney transplant recipients is scarce. Our main aim was to show the effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
We also recommend Trading Suppliers and Manufacturers of Paricalcitol (cas 131918-61-1). Pls Click Website Link as below: cas 131918-61-1 suppliers
Prev:Effects of oral Paricalcitol (cas 131918-61-1) therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism
Next:Inhibition of human leukaemia 60 cell growth by mercapturic acid metabolites of phenylethyl isothiocyanate) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Effects of oral Paricalcitol (cas 131918-61-1) therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism08/01/2019
- Paricalcitol (cas 131918-61-1) Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients07/31/2019
- Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol (cas 131918-61-1)07/30/2019
- Perfil antiinflamatorio del Paricalcitol (cas 131918-61-1) en el receptor de trasplante renal07/29/2019
- Vitamin D receptor activation by Paricalcitol (cas 131918-61-1) and insulin resistance in CKD07/28/2019
- Paricalcitol (cas 131918-61-1) alleviates lipopolysaccharide-induced depressive-like behavior by suppressing hypothalamic microglia activation and neuroinflammation07/27/2019
- Anti-inflammatory profile of Paricalcitol (cas 131918-61-1) in kidney transplant recipients07/26/2019